Patents by Inventor Masami Ohtsuka
Masami Ohtsuka has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8785438Abstract: A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.Type: GrantFiled: March 13, 2013Date of Patent: July 22, 2014Assignee: Daiichi Sankyo Company, LimitedInventors: Masami Ohtsuka, Noriyasu Haginoya, Masanori Ichikawa, Hironori Matsunaga, Hironao Saito, Yoshihiro Shibata, Tomoyuki Tsunemi
-
Patent number: 8436012Abstract: A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.Type: GrantFiled: November 24, 2010Date of Patent: May 7, 2013Assignee: Daiichi Sankyo Company, LimitedInventors: Masami Ohtsuka, Noriyasu Haginoya, Masanori Ichikawa, Hironori Matsunaga, Hironao Saito, Yoshihiro Shibata, Tomoyuki Tsunemi
-
Patent number: 8431614Abstract: There is provided a novel loxoprofen derivative that has no side effect such as a gastrointestinal disorder and also has excellent anti-inflammatory and analgesic effects and is represented by the following formula (I) or (II): (wherein R1 and R2 each represent a halogen atom or a substituted or unsubstituted phenyl group) or a pharmacologically acceptable salt thereof. In the derivative, the halogen atom is selected from a chlorine atom, a bromine atom, a fluorine atom, and an iodine atom, and a substituent of the substituted phenyl group is a halogen atom, a hydroxyl group, a substituted or unsubstituted lower alkyl group, a lower alkylthio group, a lower alkoxy group, a nitro group, an amino group, or a carboxyl group.Type: GrantFiled: February 18, 2010Date of Patent: April 30, 2013Assignees: LTT Bio-Pharma Co., Ltd., National University Corporation Kumamoto UniversityInventors: Toru Mizushima, Masami Ohtsuka, Yoshinari Okamoto, Naoki Yamakawa
-
Publication number: 20120016158Abstract: There is provided a novel loxoprofen derivative that has no side effect such as a gastrointestinal disorder and also has excellent anti-inflammatory and analgesic effects and is represented by the following formula (I) or (II): (wherein R1 and R2 each represent a halogen atom or a substituted or unsubstituted phenyl group) or a pharmacologically acceptable salt thereof. In the derivative, the halogen atom is selected from a chlorine atom, a bromine atom, a fluorine atom, and an iodine atom, and a substituent of the substituted phenyl group is a halogen atom, a hydroxyl group, a substituted or unsubstituted lower alkyl group, a lower alkylthio group, a lower alkoxy group, a nitro group, an amino group, or a carboxyl group.Type: ApplicationFiled: February 18, 2010Publication date: January 19, 2012Applicants: LTT BIO-PHARMA CO., LTD., National University Corporation, Kumamoto UniversityInventors: Toru Mizushima, Masami Ohtsuka, Yoshinari Okamoto, Naoki Yamakawa
-
Publication number: 20110262548Abstract: A PGE1 derivative is provided which has an excellent sustained, slow-release PGE1 action. In addition, a PGE1-derivative-containing nanoparticle produced using this PGE1 derivative is provided, which effectively targets an affected site, has excellent drug slow-release properties, and has reduced side effects. This PGE1-derivative-containing nanoparticle is a nanoparticle containing a prostaglandin E1 derivative represented by the following formula (1) (wherein n denotes an integer of 1 to 12), obtained by hydrophobicizing the prostaglandin E1 derivative with a metal ion, and reacting the hydrophobicized prostaglandin E1 derivative with poly L-lactic acid or a poly(L-lactic acid/glycolic acid) copolymer and a poly DL- or L-lactic acid-polyethylene glycol block copolymer or a poly(DL- or L-lactic acid/glycolic acid)-polyethylene glycol block copolymer.Type: ApplicationFiled: October 16, 2009Publication date: October 27, 2011Applicant: LTT Bio-Pharma Co., Ltd.Inventors: Toru Mizushima, Masami Ohtsuka, Yoshinari Okamoto
-
Publication number: 20110082138Abstract: A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: November 24, 2010Publication date: April 7, 2011Applicant: Daiichi Sankyo Company, LimitedInventors: Masami Ohtsuka, Noriyasu Haginoya, Masanori Ichikawa, Hironori Matsunaga, Hironao Saito, Yoshihiro Shibata, Tomoyuki Tsunemi
-
Patent number: 7056917Abstract: A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, R1 and R2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W1 represents —CH?CH—, —CH2O—, —CH2CH2— or the like; R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R4 represents hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R5 represents a cyclic alkyl group, an aryl group or the like); W2 represents a single bond or —C(R8)?C(R9)— (R8 and R9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.Type: GrantFiled: April 26, 2001Date of Patent: June 6, 2006Assignees: Daiichi Pharmaceutical Co., Ltd., Trine Pharmaceuticals, Inc.Inventors: Kiyoshi Nakayama, Masami Ohtsuka, Haruko Kawato, William Watkins, Jason Zhang, Monica Palme, Aesop Cho
-
Publication number: 20060106034Abstract: A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, R1 and R2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W1 represents —CH?CH—, —CH2O—, —CH2CH2— or the like; R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R4 represents hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R5 represents a cyclic alkyl group, an aryl group or the like); W2 represents a single bond or —C(R8)?C(R9)?(R8 and R9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.Type: ApplicationFiled: December 29, 2005Publication date: May 18, 2006Applicants: Daiichi Pharmaceutical Co., Ltd., Trine Pharmaceuticals, Inc.Inventors: Kiyoshi Nakayama, Masami Ohtsuka, Haruko Kawato, William Watkins, Jason Zhang, Monica Palme, Aesop Cho
-
Publication number: 20050009843Abstract: A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): wherein, R1 and R2 represent hydrogen atom, a halogen atom, hydroxyl group or the like, W1 represents —CH?CH—, —CH2O—, —CH2CH2— or the like; R3 represents hydrogen atom, a halogen atom, hydroxyl group or an amino group; R4 represents hydrogen atom, a group of —OZ0-4R5 (Z0-4 represents an alkylene group, a fluorine-substituted alkylene group or a single bond, and R5 represents a cyclic alkyl group, an aryl group or the like); W2 represents a single bond or —C(R8)?C(R9)—(R8 and R9 represent hydrogen atom, a halogen atom, a lower alkyl group or the like, Q represents an acidic group, but W2 and Q may together form vinylidenethiazolidinedione or an equivalent heterocyclic ring; m and n represent an integer of 0 to 2, and q represents an integer of 0 to 3.Type: ApplicationFiled: April 24, 2002Publication date: January 13, 2005Inventors: Kiyoshi Nakayama, Masami Ohtsuka, Haruko Kawato, Ryo Okumura, Kazuki Hoshino, William Watkins, Jason Zhang, Monica Palme, Aesop Cho
-
Publication number: 20030092720Abstract: A medicament for preventive and/or therapeutic treatment of a microbial infection which comprises as an active ingredient a compound represented by the following general formula (I): 1Type: ApplicationFiled: April 26, 2001Publication date: May 15, 2003Applicant: DAIICHI PHARMACEUTICAL CO., LTDInventors: Kiyoshi Nakayama, Masami Ohtsuka, Haruko Kawato, William Watkins, Jason Zhang, Monica Palme, Aesop Cho
-
Patent number: 6399629Abstract: Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.Type: GrantFiled: July 1, 1998Date of Patent: June 4, 2002Assignee: Microcide Pharmaceuticals, Inc.Inventors: Suzanne Chamberland, Yohei Ishida, Ving J Lee, Roger Leger, Kiyoshi Nakayama, Toshiharu Ohta, Masami Ohtsuka, Thomas E. Renau, William J. Watkins, Zhijia J. Zhang